Lv6
2670 积分 2022-02-25 加入
First-line Pembrolizumab Plus Lenvatinib for Advanced Non–clear-cell Renal Cell Carcinoma: Updated Results from the Phase 2 KEYNOTE-B61 Trial
1个月前
已完结
Perioperative Apalutamide in High-Risk Localized Prostate Cancer
1个月前
已完结
NSCLC: Five trials to watch
1个月前
已关闭
Radiotherapy for more efficacious novel anticancer drugs: a position paper from the European Society for Radiotherapy and Oncology (ESTRO) focus group on novel systemic therapies and radiotherapy
1个月前
已完结
Targeting Androgen Receptor Mutations in Metastatic Castration-Resistant Prostate Cancer with a Novel Androgen Biosynthesis Inhibitor
2个月前
已完结
First-Line Zongertinib in Advanced HER2 -Mutant Non–Small-Cell Lung Cancer
2个月前
已完结
Enzalutamide in Biochemically Recurrent Prostate Cancer
2个月前
已完结
Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer
2个月前
已完结
Predictive value of early PSMA upregulation for the response to enzalutamide ± 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial
2个月前
已完结
Deutenzalutamide, a novel androgen receptor inhibitor, after progression on docetaxel and abiraterone in metastatic castration-resistant prostate cancer: results from the randomized phase III HC-1119-04 trial
2个月前
已关闭
皖公网安备34019202002308
